Expertise in
3
conditions

Elisa Roncoroni

Pavia, IT 
Expertise in
3
conditions
Pavia, IT 

Overview

Elisa Roncoroni practices practicing medicine in Pavia, Italy.

Ms. Roncoroni is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Essential Thrombocythemia, Myeloproliferative Neoplasms (MPN), and Polycythemia Vera.

She is actively involved in clinical research, co-authoring 18 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Pavia, Italy
Other Locations
San Matteo, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Procedure
Study Drugs: AOP2014, Acetylsalicylic acid
Study Phase: Phase 2
Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.
Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.
Enrollment Status: Completed
Publish Date: November 30, 2021
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
View 1 Less Clinical Trial

18 Total Publications

Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study.
Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study.
Journal: HemaSphere
Published: February 05, 2026

Frequently Asked Questions about Elisa Roncoroni

Is Elisa Roncoroni a top-rated expert for Myelofibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Elisa Roncoroni is classified as an Advanced expert for Myelofibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Elisa Roncoroni participate in research or clinical trials?

Yes. Elisa Roncoroni has published 18 articles and abstracts on conditions like Myelofibrosis. You can view a list of Elisa Roncoroni's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Roncoroni's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile